# Infectious Disease Agents: Antibiotics – Inhaled

**LENGTH OF AUTHORIZATIONS:**  28 days

**PRIOR AUTHORIZATION CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to medications not requiring prior approval

- Contraindication to or drug interaction with medications not requiring prior approval

- History of unacceptable/toxic side effects to medications not requiring prior approval

- Diagnosis of cystic fibrosis with pseudomonas-related infection

- Age limit of 6 and older for tobramycin products

- Age limit of 7 and older for aztreonam

- “Pulse” dosing cycles of 28 days on drug, followed by 28 days off drug

**ADDITIONAL INFORMATION:**

The requested medication may be approved if the following is true:

- If there has been no less than a **28-day** trial of at least **one preferred** medication

**ADDITIONAL CRITERIA FOR AMIKACIN:**

**LENGTH OF AUTHORIZATIONS**:

Initial authorization 180 days

Subsequent authorizations 365 days

1. Clinical criteria for initial authorization:

    - Diagnosis of *Mycobacterium avium* complex (MAC) lung disease; and

    - Patient has not achieved negative sputum cultures after a minimum of 180 consecutive days of a multidrug background regimen therapy (e.g. macrolide, rifampin, & ethambutol)

2. Criteria for subsequent authorizations

    - Evidence of culture conversion (negative sputum culture)

3. Dose will be limited to 1 dose per day
